Business Wire
21 Aug 2026, 13:06 UTC · 3w ago
Verdict
Headline takes no side. We score SRRK +0.30 across one claim — moderately bullish.
+0.30moderately bullish
More positive than 58% of ticker scores this week
What the story claims
1 claim · scored −1 bearish … +1 bullish
Scholar Rock has successfully removed Catalent Indiana LLC as a commercial fill-finish facility from its apitegromab BLA for the treatment of spinal muscular atrophy.
More positive than 65% of claims this week
Which stocks this story touches
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 58% of ticker scores this week
The company successfully mitigated a supply chain risk by removing a specific facility from its BLA.
Near neutral — 90% of ticker scores this week are stronger
Mentioned only as the parent company of a facility being removed from a partner's application.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Accesswire
3h ago
−10.6%
Price is moving against the score
$49.37 vs $55.25 close before publication (Aug 20) · not market-adjusted
SRRK chart →
